A substantial advancement in diabetes management is emerging with the approval of tirzepatide at a dosage of 45mg. This new offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://listfav.com/story23098120/groundbreaking-introduction-tirzepatide-strength-for-blood-sugar-management